Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • biglabowski99 biglabowski99 Feb 11, 2013 7:30 PM Flag

    new cabo vid liver cancer

    type the u tube url followed by watch?v=O6O9c6b2E0g

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • $$$$

      Good find, biglabowski...
      I found the same video on OncLive, and stole the following transcript excerpt suggesting a strong OS signal from the P2 RDT.
      Good stuff here...and a greatargument for a P3 Cabo trial in HCC.

      "Cabozantinib, a multikinase inhibitor that blocks both VEGFR2 and MET, demonstrated impressive results in a phase II trial, Abou-Alfa notes. Overall, the randomized discontinuation trial included 41 patients and found that treatment with cabozantinib improved median overall survival (OS) by 15.1 months."

      GLTA

      • 1 Reply to wilderguide
      • "Overall, the randomized discontinuation trial included 41 patients and found that treatment with cabozantinib improved median overall survival (OS) by 15.1 months."

        You have to be really, really careful about assigning credibility whenever you find a release of previously unreported data. Information that is not already in the public realm is closely held and the credit for that information will either go to the lead investigator or Exelixis itself. You guys heard this guy correctly, but he misspoke. He was discussing the 2nd line HCC data. 15.1 months was the median survival for the cabo arm, and that does represent an improvement over historic data, but that is not the same as improving OS by 15.1 months.

 
EXEL
3.44-0.05(-1.43%)Jul 2 4:00 PMEDT